Dépistage du cancer du poumon : mise au point, actualités et perspectives

Abstract

Lung cancer is the leading cause of cancer death in France and worldwide (20% of cancer deaths). This mortality is partly linked to an overrepresentation of metastatic stages at diagnosis (approximately 55% of lung cancers at diagnosis). Low-dose chest CT in a target population to detect early forms accessible to radical treatment has been evaluated through multiple randomized trials (NLST, NELSON, MILD, DANTE…). These trials demonstrated a reduction in lung cancer specific mortality. The current problem is to integrate a CT screening policy CT at a national level, which should be both efficient and cost-effective, while presenting the least harms for the eligible population. Finally, it is necessary to optimize the participation of the eligible population and particularly in the most deprived areas and ensure the proper implementation of smoking cessation measures.